argenx Announces Results of Extraordinary General Meeting of Shareholders

argenx (Euronext & Nasdaq: ARGX) announced the results of its Extraordinary General Meeting held on November 18, 2025 in Amsterdam.

Rhea-AI Summary

argenx (Euronext & Nasdaq: ARGX) announced the results of its Extraordinary General Meeting held on November 18, 2025 in Amsterdam.

The sole agenda item, the company’s remuneration policy, was approved by the required majority with 95.67% of votes in favor and 91.1% of share capital represented at the meeting. Voting results and all related meeting documents are available on the company’s investor website at www.argenx.com/investors/shareholder-meetings.

Argus Nov 19 session

-0.43% close to close Open Argus

Details

News Market Reaction – ARGX

On Nov 19, the first trading day after this news, ARGX closed 0.43% below the previous close.

Data tracked by StockTitan Argus for the Nov 19 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

November 18, 2025 – 10:01 PM CET

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Extraordinary General Meeting of shareholders held on November 18, 2025.

The remuneration policy, which was the sole voting item on the agenda, was approved by the required majority of votes. The Company’s remuneration policy was approved by a 95.67% majority, with 91.1% of share capital represented at the Extraordinary General Meeting.

The voting result and all documents relating to the shareholders’ meeting will be available on the argenx
website at www.argenx.com/investors/shareholder-meetings.

About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.

For further information, please contact:  

Media:

Ben Petok
Bpetok@argenx.com

Investors:

Alexandra Roy
aroy@argenx.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did argenx shareholders vote on at the November 18, 2025 EGM (ARGX)?

Shareholders voted to approve the company’s remuneration policy as the sole agenda item.

What percentage voted in favor of argenx’s remuneration policy at the November 18, 2025 EGM (ARGX)?

The remuneration policy was approved by a 95.67% majority of votes.

How much share capital was represented at argenx’s November 18, 2025 EGM (ARGX)?

91.1% of the company’s share capital was represented at the Extraordinary General Meeting.

Where can I find the full voting results and documents from argenx’s November 18, 2025 EGM (ARGX)?

All voting results and meeting documents are available at www.argenx.com/investors/shareholder-meetings.

Does the approval of the remuneration policy on November 18, 2025 change argenx’s executive pay immediately (ARGX)?

The vote approves the policy; implementation details or timing are not specified in the meeting results.